Liothyronine

Cytomel is labeled for congenital or acquired primary, secondary, or tertiary hypothyroidism; TSH suppression with surgery and radioiodine for well-differentiated thyroid cancer; and a thyroid suppression diagnostic test. It is not indicated for benign nodules or nontoxic diffuse goiter in iodine-sufficient patients, or hypothyroidism during recovery from subacute thyroiditis. ATA guidance favors levothyroxine for routine replacement; the labeled T3 regimens below are not a recommendation to replace it universally.

The XGen IV product is labeled for myxedema coma or precoma, a medical emergency requiring monitored hospital treatment. Its pediatric safety and efficacy are not established. Oral Cytomel is unsuitable for this emergency because absorption is unpredictable. The IV and oral products have separate labels and are not a simple dose-for-dose substitution.

Take Cytomel once daily. Adjust for clinical response, disease cause, age, and cardiac disease. The age-related pediatric maintenance examples in the label are possible requirements, not automatic targets.

Cancer TSH targets are individualized to the oncologic situation; the label provides no universal dose. The labeled suppression test is 75–100 mcg daily for 7 days with radioactive iodine uptake before and afterward, under specialist supervision. When switching from levothyroxine, stop it and start low-dose Cytomel, accounting for residual T4 effects over several weeks; no universal conversion ratio is supplied.

The IV label recommends an adult initial 25–50 mcg; 10–20 mcg with known or suspected cardiovascular disease. Subsequent doses require continuous clinical assessment, spaced at least 4 and no more than 12 hours apart. Its historical case-report discussion of at least 65 mcg/day is not a mandatory target, and experience above 100 mcg/day is limited. Give IV only, with glucocorticoids and support of ventilation, circulation, electrolytes, and the precipitating illness.

The 2026 joint consensus favors IV levothyroxine initially and describes T3 as controversial. A cautious option is T3 2.5–10 mcg IV every 8 hours if improvement is inadequate; an alternative described strategy adds a 10–25 mcg IV T3 loading dose to IV T4. Lower doses are appropriate with older age or cardiovascular risk. These specialist consensus approaches differ from the older IV label and require an individualized hospital protocol.

Resume oral therapy after stabilization and ability to take medication; start oral T3 low and titrate. When changing to oral T4, the IV label cautions that T4 action is delayed and IV treatment may need gradual discontinuation. Neither label supplies a fixed renal or hepatic adjustment algorithm. The IV label highlights renal excretion and cautious dosing and renal monitoring in older patients.

Cytomel formally lists uncorrected adrenal insufficiency. The IV label additionally lists untreated thyrotoxicosis, hypersensitivity to active or other constituents, and concomitant artificial rewarming. These formulation-specific lists should not be conflated. Ingredient hypersensitivity reactions can still occur with oral products.

Both labels warn that thyroid hormones must not be used for weight loss. Replacement-range doses do not reduce weight in euthyroid people; larger doses can cause life-threatening toxicity, especially with sympathomimetic appetite suppressants.

Excess replacement produces hyperthyroid symptoms: palpitations, tremor, anxiety, insomnia, sweating, heat intolerance, diarrhea, weight loss, and muscle weakness. Serious events include arrhythmias, ischemia, seizures, shock, coma, or death. Pediatric reports include intracranial hypertension and skeletal maturation abnormalities; ingredient allergy can include angioedema. IV emergency experience reports important cardiopulmonary events. Suspected excess dosing requires urgent clinical or poison-center assessment, dose withdrawal/reduction, and monitored supportive care; symptoms may be delayed.

Give oral T3 at least 4 hours before bile acid sequestrants and ion-exchange resins such as sevelamer or sodium polystyrene sulfonate, or monitor TSH as the label directs. Estrogens, androgens, glucocorticoids, salicylates, phenytoin, and other binding-displacement medicines alter total thyroid measurements; interpret free hormone and clinical findings rather than assuming every total-level change needs a dose increase. Phenobarbital or rifampin may increase thyroid-hormone clearance.

Monitor coagulation with oral anticoagulants because thyroid replacement can increase anticoagulant response. Monitor glucose and adjust diabetes treatment if needed. Digoxin effects or requirements may change with thyroid status; review levels and response. Tricyclic/tetracyclic antidepressants can add arrhythmia and CNS toxicity; sertraline may increase T3 requirements. Ketamine can cause marked hypertension/tachycardia. Sympathomimetics and vasopressors increase coronary and arrhythmia risk; use carefully, especially IV. Certain tyrosine kinase inhibitors cause hypothyroidism and need thyroid-function monitoring.

Cytomel labeling reports no increased major birth-defect or miscarriage rates in available postmarketing experience and says replacement should continue, with pregnancy and postpartum laboratory-guided adjustment. This does not establish T3 as preferred pregnancy therapy: The 2026 ATA guideline recommends levothyroxine alone and advises against T3 preparations both when planning pregnancy and during pregnancy because adequate maternal T4 is important for fetal brain development. Arrange prompt endocrine/obstetric review and supervised transition rather than leaving hypothyroidism untreated.

The current oral label reports liothyronine in human milk but insufficient infant-effect information and no milk-production data; weigh breastfeeding benefits, maternal need, and potential effects. The older IV label advises caution using legacy wording. Neither label supports a quantified safe infant exposure or an automatic prohibition; an individualized thyroid and lactation assessment is needed.

Oral pediatric replacement is labeled, with close development, growth, bone maturation, and thyroid-function assessment; avoid both underreplacement and excess. This does not establish a pediatric IV emergency dose. Older adults and those with cardiac disease need low starts and cautious titration. No standardized renal or hepatic algorithm is provided; assess organ disease, interacting treatment, and response, with renal caution particularly in older IV recipients.

Liothyronine is synthetic triiodothyronine, influencing nuclear gene transcription and metabolic activity across organ systems. Oral activity begins within hours and reaches a maximum over roughly 2–3 days. The IV label describes measurable metabolic effects within 2–4 hours and maximal response within 2 days. These are not promises of emergency clinical recovery.

The oral label describes about 95% absorption within 4 hours and a biological half-life near 2.5 days. T3 is less tightly protein-bound than T4; metabolism involves deiodination and conjugation, with renal and fecal elimination. The IV label has no pharmacokinetic studies in myxedema coma/precoma patients; healthy or oral observations cannot define an emergency clearance-based regimen.

For primary hypothyroidism monitor TSH after initiation or changes; total T3 can assess earlier response. Once stable, reassess adults every 6–12 months and with clinical change. For secondary/tertiary disease, use serum T3 in the normal range rather than TSH alone. Monitor pediatric growth and development; age ≥3 stable children have labeled thyroid checks every 3–12 months. Track pulse, cardiac symptoms, glucose, bone risk, adherence, and interacting drugs. Emergency care requires continuous cardiovascular and respiratory assessment; the 2026 consensus uses alternate-day thyroid tests and cautions against using slow-normalizing TSH to guide acute response.

Verify micrograms and the exact product, follow the prescribed schedule, and avoid weight-loss use or self-directed conversion from T4. Report chest pain, rapid/irregular heartbeat, breathlessness, marked tremor, or severe allergy promptly. Share all medicines and planned surgery; contact the treating team promptly for pregnancy or breastfeeding. Long-term replacement is often lifelong, but the diagnosis and indication determine duration.

Pfizer Cytomel tablets are round and white to off-white: 5 mcg marked KPI / 115; scored 25 mcg KPI / 116 and scored 50 mcg KPI / 117. Bottles of 100 have NDCs 60793-115-01, 60793-116-01, and 60793-117-01. XGen injection is a 1 mL amber vial containing 10 mcg/mL, single-vial carton NDC 39822-0151-1. Other manufacturers may look different.

Covered products: oral tablets 5, 25, and 50 mcg; sterile IV solution 10 mcg/mL, containing 6.8% alcohol by volume. The injection is not for IM or subcutaneous use. Compounded products, desiccated thyroid, and fixed T4/T3 combinations are outside this product-specific reference.

Cytomel: store at 15–30°C (59–86°F). XGen injection: refrigerate at 2–8°C (36–46°F). Use the exact injection label and hospital handling protocol; an oral storage instruction must not be applied to the vial.